Lexicon Pharmaceuticals (LXRX) Short-term Investments (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Short-term Investments data on file, last reported at $132.6 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $132.6 million, changed 0.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $132.6 million (changed 0.47% YoY), and the FY2025 annual result was $61.9 million, down 63.86% from the prior year.
• Short-term Investments improved to $132.6 million in Q1 2026 per LXRX's latest filing, from $61.9 million in the prior quarter.
• Over five years, Short-term Investments peaked at $274.3 million in Q2 2024 and troughed at $27.0 million in Q1 2022.
• A 5-year average of $135.0 million and a median of $132.0 million in 2025 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments jumped 307.53% in 2022, then sank 70.38% in 2025.
• A 5-year view of Short-term Investments shows it stood at $92.0 million in 2022, then soared by 60.37% to $147.6 million in 2023, then advanced by 16.09% to $171.3 million in 2024, then tumbled by 63.86% to $61.9 million in 2025, then jumped by 114.15% to $132.6 million in 2026.
• Business Quant data shows LXRX's Short-term Investments at $132.6 million in Q1 2026, $61.9 million in Q4 2025, and $66.3 million in Q3 2025.